Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho Sells 9,039 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 9,039 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $399,523.80. Following the completion of the sale, the general counsel now directly owns 195,037 shares of the company’s stock, valued at $8,620,635.40. The trade was a 4.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $44.88 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The company has a market capitalization of $4.20 billion, a PE ratio of -19.10 and a beta of 0.52. The stock has a fifty day moving average of $39.94 and a 200-day moving average of $23.59. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.19.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds have recently modified their holdings of SRRK. GAMMA Investing LLC raised its holdings in Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after acquiring an additional 1,031 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Scholar Rock by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after acquiring an additional 514 shares in the last quarter. Quarry LP boosted its stake in Scholar Rock by 3,443.3% in the 3rd quarter. Quarry LP now owns 4,500 shares of the company’s stock worth $36,000 after purchasing an additional 4,373 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in Scholar Rock in the 2nd quarter worth approximately $100,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SRRK has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, October 14th. HC Wainwright upped their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Piper Sandler lifted their price target on Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Wedbush restated an “outperform” rating and issued a $47.00 price objective on shares of Scholar Rock in a report on Thursday, January 9th. Finally, BMO Capital Markets raised their target price on Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, October 11th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.